$IMNN

Eylward Susan sold $21K of IMNN

Eylward Susan (General Counsel and Corp Sec) sold 11,800 shares of Imunon, Inc. (IMNN) at $1.75 on 2026-06-29.

Original reporting
SEC EDGAR · Eylward Susan
Published Jun 29, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 7:02 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IMNN
Neutral
medium confidence
Mentioned
$IMNN
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IMNNNeutralLow
01

Why it matters

The disclosure updates the insider trading record and may influence short-term sentiment, but it does not change guidance, trials, or business fundamentals.

02

Market read

Traders may monitor IMNN for insider activity, but this specific sale is unlikely to be a standalone driver.

03

What to watch

The filing does not indicate whether the sale was part of a broader pattern, whether other insiders sold/bought, or whether the insider retained meaningful exposure after the sale.

Relevance 3/10Novelty 3/10Timing: filed 2026-06-29, after-hours/close timing for the same trading day

Background

The article is an SEC Form 4 insider transaction disclosure for Imunon, Inc. (IMNN).

Company-level read

Ticker impact

$IMNNNeutralMedium confidence
Context

Imunon general counsel Eylward Susan sold 11,800 shares on 2026-06-29 at $1.7520, totaling $20,673.60, per Form 4.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment around insider selling.

Evidence & confidence

The filing is a primary-source Form 4, but the transaction is small relative to typical company market caps and provides no new operational or financial information.

Market effects

No clear sector read-through from a single small insider sale.

None.

None.

Counterpoint

Insider sales can be planned for liquidity or tax needs; the absence of a stated 10b5-1 plan does not necessarily imply negative fundamentals.

Key entities

  • Imunon, Inc.

    Company whose insider transaction was disclosed on SEC Form 4.

  • Eylward Susan

    General Counsel and Corp Sec who sold shares on 2026-06-29.

Related articles

$IMNNMed

EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study - Im

Imunon Inc. (NASDAQ:IMNN) updated its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said site activation and enrollment are ahead of forecasts, with full enrollment expected by Q2 2029. It reported no cytokine release syndrome or serious immune-related adverse events and noted two interim analyses that could support an early BLA. Shares rose 1.95% to $1.57 premarket.

$IMNNMed

Imunon, Inc.: IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

IMUNON (Nasdaq: IMNN) provided an update on its pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian cancer. The company said enrollment is ahead of plan, with a study rate of about 0.5 patients per site per month versus 0.3 planned, and it now expects completion in Q2 2029. It reported no cytokine release syndrome and comparable safety versus control.

$IMNNMedAI 9/10

Imunon Secures $10 Million Funding Package to Advance Phase 3 Ovarian Cancer Study (IMNN)

Imunon Inc. (NASDAQ:IMNN) said it secured a $10 million financing package to advance its Phase 3 OVATION 3 ovarian cancer trial of IMNN-001. The company will receive $2.5 million via 250 non-redeemable, non-convertible preferred shares and about $7.72 million through two secured promissory notes at 8% and 5% interest, maturing in 18 months. Imunon cited updated Phase 2 survival data.